Current views on inducing synthetic lethal RNAi responses in the treatment of cancer

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis

(2015) Sidi Chen et al.   CELL

Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer

(2015) S. Baumer et al.   CLINICAL CANCER RESEARCH

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates

(2015) Emily P. Thi et al.   NATURE

The evolutionary history of lethal metastatic prostate cancer

(2015) Gunes Gundem et al.   NATURE

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

(2015) Ana Bosch et al.   Science Translational Medicine

Synthetic Lethality Screen Identifies RPS6KA2 as Modifier of Epidermal Growth Factor Receptor Activity in Pancreatic Cancer

(2015) Nada Milosevic et al.   NEOPLASIA

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells

(2014) Jian Kang et al.   BMC CANCER

Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening

(2014) Zongxiang Zhou et al.   BMC CANCER

Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality

(2014) Livnat Jerby-Arnon et al.   CELL

RNAi Screen Identifies a Synthetic Lethal Interaction between PIM1 Overexpression and PLK1 Inhibition

(2014) R. van der Meer et al.   CLINICAL CANCER RESEARCH

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

(2014) N. A. O'Brien et al.   CLINICAL CANCER RESEARCH

Current issues of RNAi therapeutics delivery and development

(2014) D. Haussecker   JOURNAL OF CONTROLLED RELEASE

Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles

(2014) Yang Liu et al.   JOURNAL OF CONTROLLED RELEASE

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications

(2014) Bryan R Meade et al.   NATURE BIOTECHNOLOGY

Applying Synthetic Lethality for the Selective Targeting of Cancer

(2014) Donal P. McLornan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small RNA combination therapy for lung cancer

(2014) W. Xue et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

(2014) Y. Dong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of siRNA Payloads to Target KRAS-Mutant Cancer

(2014) T. L. Yuan et al.   Cancer Discovery

Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition

(2014) Patricia A. Possik et al.   Cell Reports

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

(2013) K. Cramer-Morales et al.   BLOOD

Application of the concept synthetic lethality toward anticancer therapy: A promise fulfilled?

(2013) Dan Canaani   CANCER LETTERS

Glioblastoma and Other Malignant Gliomas

(2013) Antonio Omuro   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Delivery materials for siRNA therapeutics

(2013) Rosemary Kanasty et al.   NATURE MATERIALS

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug

(2013) X. Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RNA-Guided Human Genome Engineering via Cas9

(2013) P. Mali et al.   SCIENCE

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment

(2013) M. Nishimura et al.   Cancer Discovery

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies

(2012) Michael Steckel et al.   CELL RESEARCH

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Synthetic lethality between Rb, p53 and Dicer or miR-17–92 in retinal progenitors suppresses retinoblastoma formation

(2012) David Nittner et al.   NATURE CELL BIOLOGY

Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4

(2012) Y. Ren et al.   Science Translational Medicine

A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells

(2012) Michel Weïwer et al.   ACS Medicinal Chemistry Letters

STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells

(2011) C. Babij et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Harnessing synthetic lethal interactions in anticancer drug discovery

(2011) Denise A. Chan et al.   NATURE REVIEWS DRUG DISCOVERY

Current prospects for RNA interference-based therapies

(2011) Beverly L. Davidson et al.   NATURE REVIEWS GENETICS

Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma

(2010) Hiroyuki Michiue et al.   CANCER BIOLOGY & THERAPY

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

(2010) Marta Puyol et al.   CANCER CELL

NRAS Mutations Are Rare in Colorectal Cancer

(2010) Natsumi Irahara et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers

(2010) Min S Kim et al.   JOURNAL OF PATHOLOGY

Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells

(2010) M. S. Goldberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rad52 inactivation is synthetically lethal with BRCA2 deficiency

(2010) Z. Feng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer

(2009) R. J. Crowder et al.   CANCER RESEARCH

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

(2009) David O Azorsa et al.   Journal of Translational Medicine

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

(2009) J. J. Molenaar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression

(2008) M. Aleku et al.   CANCER RESEARCH

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

(2008) Nicholas C Turner et al.   EMBO JOURNAL

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Origins and evolution of eukaryotic RNA interference

(2008) S SHABALINA et al.   TRENDS IN ECOLOGY & EVOLUTION